Young, C; Mueller, M. What are the best practices for COVID-19 response and control in indigenous populations in Northern Saskatchewan and in on-reserve communities? 2020 Apr 24; Document no.: EPM040901-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 24 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc27
Young, C; Dalidowicz, M; Howell-Spooner, B. What are the best practices for self-isolation for transient populations? 2020 May 26; Document no.: VPL041601-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 20 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc31
Young, C; Dalidowicz, M; Howell-Spooner, B. What are the best practices for delivery of harm reduction services to people who are self-isolating? 2020 May 27; Document no.: VPL041602-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 15 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc35
Badea, A; Abonyi, S; Hanson, L; Bourassa, C; Dalidowicz, M; Young, C; Howell-Spooner, B. What are the best practices for self-isolation for transient populations? 2020 Apr 19; Document no.: VPL041601 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 11 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc40
Badea, A; Fornssler, B; Dalidowicz, M; Young, C; Howell-Spooner, B. What are the best practices for delivery of harm reduction services to people who are self-isolating 2020 Apr 20; Document no.: VPL041602 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 10 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc51
Young, C; Dalidowicz, M; Mueller, M. What is the period of communicability of symptomatic SARS-CoV-2? 2020 Apr 25; Document no.: INF042401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 35 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc56
Williams-Roberts, H; Lee, S; Young, C; Dalidowicz, M; Mueller, M. What is the period of communicability of symptomatic SARS CoV-2? 2020 Apr 27; Document no.: INF042401 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 24 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc57
Dalidowicz, M; Young, C; Mueller, M. What are the risk factors for severity and death associated with COVID-19? 2020 May 12; Document no.: EPM050901-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 48 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc79
Williams-Roberts, H; Groot, G; Dalidowicz, M; Young, C; Mueller, M. What are the risk factors for severity and death associated with COVID-19? 2020 May 17; Document no.: EPM050901 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 14 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc87
Dalidowicz, M; Young, C; Mueller, M. What proportion of disease transmission is due to persons who are asymptomatic over the entire course of illness? 2020 May 13; Document no.: EPM051301-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 35 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc88
Williams-Roberts, H; Groot, G; Dalidowicz, M; Young, C; Mueller, M. What are the risk factors for severity and death associated with COVID-19? 2020 May 17; Document no.: EPM050901 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. (CEST table) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc89
Dalidowicz, M; Mueller, M. What are the fatality rates associated with COVID-19 for ICU, hospitalized, and patients discharged from ICU to general wards? 2020 May 21; Document no.: EPM052101-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 24 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc102
Williams-Roberts, H; Basran, J; Dalidowicz, M; Mueller, M. What are the fatality rates associated with COVID-19 for ICU, hospitalized, and patients discharged from ICU to general wards? 2020 May 25; Document no.: EPM052101 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 25 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc103
Williams-Roberts, H; Basran, J; Dalidowicz, M; Mueller, M. What are the fatality rates associated with COVID-19 for ICU, hospitalized, and patients discharged from ICU to general wards? 2020 May 25; Document no.: EPM052101 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. (CEST table) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc104
Williams-Roberts, H; Basran, J; Dalidowicz, M; Young, C; Mueller, M. What proportion of disease transmission is due to persons who are asymptomatic over the entire course of illness? 2020 Jun 2; Document no.: EPM051301 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 33 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc114
Miller, L; Fox, L. How is COVID-19 transmitted from person-to-person and what is the most common source of transmission? 2020 Dec 15; Document no.: INF121501-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 16 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc223
Vanstone, J; Miller, L; Fox, L. How is COVID-19 transmitted from person-to-person and what is the most common source of transmission? 2020 Dec 15; Document no.: INF121501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 11 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc226
Vanstone, J; Miller, L; Fox, L. How is COVID-19 transmitted from person-to-person and what is the most common source of transmission? 2020 Dec 17; Document no.: INF121501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. (CEST table) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc227
Young, C; Howell-Spooner, B. What is the duration of immunity for COVID-19 in previously infected patients? 2020 Dec 29; Document no.: INF090101v3-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 39 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc231
Jagwani, M; Lee, S; Shumilak, G; Reeder, B; Groot, G; Hernandez, L; Howell-Spooner, B; Miller, L. How effective are COVID-19 vaccines? 2021 Dec 26; Document no.: INF031801v019 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. (CEST Table) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc295
